Physician profile
Mridula Reddy
NPI 1568649408
$3,494.77
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,377 · 2020: $247 · 2021: $658 · 2022: $898 · 2023: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $198 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $197.88 |
| Education | $116.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $309.92 | 2019-2023 | |
| Eisai INC. | $284.42 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $260.64 | 2019-2023 | Imbruvica |
| Amgen INC. | $232.60 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $209.39 | 2019-2023 | Opdivo |
| Lilly USA, LLC | $177.37 | 2019-2023 | Retevmo, Verzenio, Jaypirca |
| Janssen Biotech, INC. | $165.52 | 2019-2022 | |
| Genentech USA, INC. | $156.99 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.46 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $120.60 | 2021-2023 | Keytruda, Lynparza |
| Celgene Corporation | $109.30 | 2021-2023 | Reblozyl |
| Janssen Pharmaceuticals, INC | $103.84 | 2019-2023 | Xarelto |
| Genzyme Corporation | $102.19 | 2019-2022 | |
| Exelixis INC. | $99.99 | 2023 | |
| Daiichi Sankyo INC. | $91.66 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mridula Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.